PF-04958242 Phase 2 trials are starting, for those who are interested there are 31 locations around the USA.
PF-04958242 is a drug being developed by Pfizer for the treatment of cognitive deficits associated with schizophrenia. It functions as an AMPA receptor modulator, meaning it regulates glutamate activity via its action on AMPA receptors. Those with schizophrenia are thought to display abnormal glutamatergic activity, specifically hyperexcitability of glutamate.